The analyst maintains a Buy rating on Akeso due to significant month-over-month and year-over-year sales growth of its drug cadonilimab, which saw a 249.5% increase year-over-year and 9.6% month-over-month. Additionally, the sales of ivonescimab also showed impressive growth, indicating strong performance and market demand.
